174 related articles for article (PubMed ID: 6380622)
21. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
22. Effect of an iron-chelating agent on lymphocyte proliferation.
Bowern N; Ramshaw IA; Badenoch-Jones P; Doherty PC
Aust J Exp Biol Med Sci; 1984 Dec; 62 ( Pt 6)():743-54. PubMed ID: 6241825
[TBL] [Abstract][Full Text] [Related]
23. Effects of iron, copper and zinc on the activity of ribonucleotide reductase in normal and leukemic human lymphocytes.
Oblender M; Carpentieri U
Anticancer Res; 1990; 10(1):123-7. PubMed ID: 2185685
[TBL] [Abstract][Full Text] [Related]
24. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
[TBL] [Abstract][Full Text] [Related]
25. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Sato A; Bacon PE; Cory JG
Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
[TBL] [Abstract][Full Text] [Related]
26. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase.
Kayyali R; Porter JB; Liu ZD; Davies NA; Nugent JH; Cooper CE; Hider RC
J Biol Chem; 2001 Dec; 276(52):48814-22. PubMed ID: 11602611
[TBL] [Abstract][Full Text] [Related]
27. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
[TBL] [Abstract][Full Text] [Related]
28. Role of iron-ATP complex in lymphocyte proliferation and infiltration.
Anghileri LJ; Ortal EM; Thouvenot P
Biol Trace Elem Res; 2005; 108(1-3):69-75. PubMed ID: 16327061
[TBL] [Abstract][Full Text] [Related]
29. In vitro inhibition of human cytomegalovirus replication by desferrioxamine.
Cinatl J; Cinatl J; Rabenau H; Gümbel HO; Kornhuber B; Doerr HW
Antiviral Res; 1994 Sep; 25(1):73-7. PubMed ID: 7811060
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.
Estrov Z; Cohen A; Gelfand EW; Freedman MH
Am J Pediatr Hematol Oncol; 1988; 10(4):288-91. PubMed ID: 3239704
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis.
Chitambar CR; Wereley JP
Cancer Res; 1995 Oct; 55(19):4361-6. PubMed ID: 7671248
[TBL] [Abstract][Full Text] [Related]
32. Ribonucleotide reductase, lipoxygenase and the intracellular low-molecular-weight iron pool.
Cooper CE; Porter JB
Biochem Soc Trans; 1997 Feb; 25(1):75-80. PubMed ID: 9056847
[No Abstract] [Full Text] [Related]
33. Inhibition of human B cell activation by diterpine forskolin: interference with B cell growth factor-induced G1 to S transition of the B cell cycle.
Muraguchi A; Miyazaki K; Kehrl JH; Fauci AS
J Immunol; 1984 Sep; 133(3):1283-7. PubMed ID: 6086754
[TBL] [Abstract][Full Text] [Related]
34. Effects of iron salts and haemosiderin from a thalassaemia patient on oxygen radical damage as measured in the comet assay.
Anderson D; Yardley-Jones A; Hambly RJ; Vives-Bauza C; Smykatz-Kloss V; Chua-Anusorn W; Webb J
Teratog Carcinog Mutagen; 2000; 20(1):11-26. PubMed ID: 10607374
[TBL] [Abstract][Full Text] [Related]
35. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators.
Nyholm S; Mann GJ; Johansson AG; Bergeron RJ; Gräslund A; Thelander L
J Biol Chem; 1993 Dec; 268(35):26200-5. PubMed ID: 8253740
[TBL] [Abstract][Full Text] [Related]
36. Deoxyadenosine (AdR) inhibition of newly activated lymphocytes: blockade at the G0-G1 interface.
Redelman D; Bluestein HG; Cohen AH; Depper JM; Wormsley S
J Immunol; 1984 Apr; 132(4):2030-8. PubMed ID: 6421932
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation and anticytomegalovirus activity of antioxidant metal chelators.
Scholz M; Blaheta RA; Markus BH; Doerr HW; Cinatl J
Transplant Proc; 1997; 29(1-2):1272-3. PubMed ID: 9123302
[No Abstract] [Full Text] [Related]
38. Role of proliferation in LAK cell development.
Ramsdell FJ; Shau H; Golub SH
Cancer Immunol Immunother; 1988; 26(2):139-44. PubMed ID: 3129192
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330
[TBL] [Abstract][Full Text] [Related]
40. The effect of deoxynucleosides on cell proliferation of peripheral blood lymphocytes treated with deferoxamine or hydroxyurea.
van der Bruggen T; Georgiou NA; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
Transfus Sci; 2000 Dec; 23(3):243-4. PubMed ID: 11099902
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
